Research progress in liver transplantation for colorectal liver metastasis

doi:10.3877/cma.j.issn.2095-3232.2025.04.002

Abstract

Abstract:

Colorectal liver metastasis (CRLM) is a common and severe complication in patients with intestinal tumors, which significantly reduces the survival rate and the quality of life of patients. Traditional treatments mainly include systemic chemotherapy, interventional therapy and targeted drug therapy, whereas the overall prognosis is relatively poor. In recent years, with the advancement in liver transplantation and the launching of multi-center clinical research, liver transplantation has gradually become a potential therapeutic option for CRLM. However, the indications, contraindications and prognostic factors of liver transplantation for colorectal cancer should be further investigated to guarantee that patients can obtain the optimal efficacy. In this article, the biological mechanism of CRLM and the potential application of liver transplantation in the treatment of CRLM were illustrated, providing novel ideas and reference for clinical management of patients with colorectal cancer and promoting in-depth research and practice in this field.

Key words: Colorectal liver metastasis (CRLM), Unresectable, Liver transplantation, Biological mechanisms, Selection criteria

Xu Lu, Hua Li. Research progress in liver transplantation for colorectal liver metastasis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(04): 508-514.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2025.04.002

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I04/508

References 39

[1]	Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology[J]. Ann Transl Med, 2019, 7(21): 609. DOI: 10.21037/atm.2019.07.91.
[2]	Zhou E, Rifkin S. Colorectal cancer and diet: risk versus prevention, is diet an intervention?[J]. Gastroenterol Clin North Am, 2021, 50(1): 101-111. DOI: 10.1016/j.gtc.2020.10.012.
[3]	Tabbal M, Alkhalifa AM, AlQattan AS, et al. Salvage liver transplantation after resection of colorectal cancer liver metastasis with favorable outcomes: a case report and review of the literature[J]. BMC Gastroenterol, 2021, 21(1): 191. DOI: 10.1186/s12876-021-01778-6.
[4]	Zhang H, Ruan Q, Chen C, et al. Activin A/ACVR2A axis inhibits epithelial-to-mesenchymal transition in colon cancer by activating SMAD2[J]. Mol Carcinog, 2023, 62(10): 1585-1598. DOI: 10.1002/mc.23601.
[5]	Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates[J]. Ann Oncol, 2005, 16(8): 1311-1319. DOI: 10.1093/annonc/mdi246.
[6]	Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective[J]. Ann Surg, 1989, 210(2): 127-138. DOI: 10.1097/00000658-198908000-00001.
[7]	Whitrock JN, Hartman SJ, Quillin RC 3rd, et al. Liver transplantation for colorectal liver metastases: is it appropriate?[J]. Adv Surg, 2023, 57(1): 171-185. DOI: 10.1016/j.yasu.2023.04.001.
[8]	Liu D, Li C, Deng Z, et al. Multi-omics analysis reveals the landscape of tumor microenvironments in left-sided and right-sided colon cancer[J]. Front Med, 2024, 11: 1403171. DOI: 10.3389/fmed.2024.1403171.
[9]	Wielandt AM, Hurtado C, Mauricio MC, et al. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: microsatellite instability, CpG island methylator phenotype and chromosomal instability[J]. Tumour Biol, 2020, 42(7): 1010428320938492. DOI: 10.1177/1010428320938492.
[10]	Mima K, Nowak JA, Qian ZR, et al. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival[J]. Oncotarget, 2016, 7(34): 55098-55109. DOI: 10.18632/oncotarget.10398.
[11]	Ilson DH. Advances in the treatment of gastric cancer[J]. Curr Opin Gastroenterol, 2020, 36(6): 525-529. DOI: 10.1097/MOG.0000000000000679.
[12]	Abdelmaksoud NM, Abulsoud AI, Doghish AS, et al. From resistance to resilience: uncovering chemotherapeutic resistance mechanisms; insights from established models[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(6): 188993. DOI: 10.1016/j.bbcan.2023.188993.
[13]	Lau DK, Burge M, Roy A, et al. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019[J]. Expert Rev Anticancer Ther, 2020, 20(4): 251-270. DOI: 10.1080/14737140.2020.1744439.
[14]	Yang L, Atakhanova N, Arellano MTC, et al. Translational research of new developments in targeted therapy of colorectal cancer[J]. Pathol Res Pract, 2023, 252: 154888. DOI: 10.1016/j.prp.2023.154888.
[15]	Chen Z, Jiang L. The clinical application of fruquintinib on colorectal cancer[J]. Expert Rev Clin Pharmacol, 2019, 12(8): 713-721. DOI: 10.1080/17512433.2019.1630272.
[16]	Penn I. Hepatic transplantation for primary and metastatic cancers of the liver[J]. Surgery, 1991, 110(4): 726-734; discussion 734-735.
[17]	Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer[J]. Ann Surg, 2013, 257(5): 800-806. DOI: 10.1097/SLA.0b013e3182823957.
[18]	Dueland S, Syversveen T, Solheim JM, et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases[J]. Ann Surg, 2020, 271(2): 212-218. DOI: 10.1097/SLA.0000000000003404.
[19]	Adam R, Piedvache C, Chiche L, et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial[J]. Lancet, 2024, 404(10458): 1107-1118. DOI: 10.1016/S0140-6736(24)01595-2.
[20]	Sakamoto K, Beppu T, Honda G, et al. Comprehensive data of 4502 patients newly diagnosed with colorectal liver metastasis between 2015 and 2017, and prognostic data of 2427 patients newly diagnosed with colorectal liver metastasis in 2013 and 2014: third report of a nationwide survey in Japan[J]. J Hepatobiliary Pancreat Sci, 2023, 30(5): 570-590. DOI: 10.1002/jhbp.1252.
[21]	Wong GYM, Diakos C, Molloy MP, et al. Prognostic models incorporating RAS mutation to predict survival in patients with colorectal liver metastases: a narrative review[J]. Cancers, 2022, 14(13): 3223. DOI: 10.3390/cancers14133223.
[22]	Takeda K, Kikuchi Y, Sawada YU, et al. Efficacy of adjuvant chemotherapy following curative resection of colorectal cancer liver metastases[J]. Anticancer Res, 2022, 42(11): 5497-5505. DOI: 10.21873/anticanres.16055.
[23]	Li S, Wei W, Feng Z, et al. Role of serum CYFRA 21-1 in diagnosis and prognostic in colorectal liver metastases[J]. Cancer Manag Res, 2023, 15: 601-614. DOI: 10.2147/CMAR.S410477.
[24]	Bonney GK, Chew CA, Lodge P, et al. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines[J]. Lancet Gastroenterol Hepatol, 2021, 6(11): 933-946. DOI: 10.1016/S2468-1253(21)00219-3.
[25]	中华医学会器官移植学分会. 中国肝移植治疗不可切除结直肠癌肝转移临床实践指南(2023版)[J]. 中华器官移植杂志, 2024, 45(8): 513-527. DOI: 10.3760/cma.j.cn421203-20240407-00082.
[26]	韩鑫, 丁元, 孙忠权, 等. 肝移植在结直肠癌肝转移中的价值[J]. 实用肿瘤杂志, 2022, 37(1): 16-22. DOI: 10.13267/j.cnki.syzlzz.2022.003.
[27]	黄忠晶, 伍子奕, 艾军华. 肝移植治疗结直肠癌肝转移的研究进展[J]. 器官移植, 2024, 15(2): 185-190. DOI: 10.3969/j.issn.1674-7445.2023188.
[28]	Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases[J]. JAMA, 2009, 302(21): 2338-2344. DOI: 10.1001/jama.2009.1755.
[29]	Hernandez-Alejandro R, Ruffolo LI, Sasaki K, et al. Recipient and donor outcomes after living-donor liver transplant for unresectable colorectal liver metastases[J]. JAMA Surg, 2022, 157(6): 524-530. DOI: 10.1001/jamasurg.2022.0300.
[30]	Kaltenmeier C, Geller DA, Ganesh S, et al. Living donor liver transplantation for colorectal cancer liver metastases: midterm outcomes at a single center in North America[J]. Am J Transplant, 2024, 24(4): 681-687. DOI: 10.1016/j.ajt.2023.09.001.
[31]	Ivanics T, Claasen MPAW, Samstein B, et al. Living donor liver transplantation for hepatocellular carcinoma within and outside traditional selection criteria: a multicentric North American experience[J]. Ann Surg, 2024, 279(1): 104-111. DOI: 10.1097/SLA.0000000000006049.
[32]	Line PD, Hagness M, Berstad AE, et al. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept[J]. Ann Surg, 2015, 262(1): e5-9. DOI: 10.1097/SLA.0000000000001165.
[33]	Königsrainer A, Templin S, Capobianco I, et al. Paradigm shift in the management of irresectable colorectal liver metastases: living donor auxiliary partial orthotopic liver transplantation in combination with two-stage hepatectomy (LD-RAPID)[J]. Ann Surg, 2019, 270(2): 327-332. DOI: 10.1097/SLA.0000000000002861.
[34]	Nadalin S, Königsrainer A, Capobianco I, et al. Auxiliary living donor liver transplantation combined with two-stage hepatectomy for unresectable colorectal liver metastases[J]. Curr Opin Organ Transplant, 2019, 24(5): 651-658. DOI: 10.1097/MOT.0000000000000695.
[35]	Lang H, Baumgart J, Mittler J. Associating liver partition and portal vein ligation for staged hepatectomy in the treatment of colorectal liver metastases: current scenario[J]. Dig Surg, 2018, 35(4): 294-302. DOI: 10.1159/000488097.
[36]	Settmacher U, Ali-Deeb A, Coubeau L, et al. Auxilliary liver transplantation according to the RAPID procedure in noncirrhotic patients: technical aspects and early outcomes[J]. Ann Surg, 2023, 277(2): 305-312. DOI: 10.1097/SLA.0000000000005726.
[37]	Gu Y, Xu S, Wang Z, et al. When immunotherapy meets liver transplantation for hepatocellular carcinoma: a bumpy but promising road[J]. Chin J Cancer Res, 2023, 35(2): 92-107. DOI: 10.21147/j.issn.1000-9604.2023.02.02.
[38]	Luo Y, Teng F, Fu H, et al. Immunotherapy in liver transplantation for hepatocellular carcinoma: pros and cons[J]. World J Gastrointest Oncol, 2022, 14(1): 163-180. DOI: 10.4251/wjgo.v14.i1.163.
[39]	Tran NH, Muñoz S, Thompson S, et al. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy[J]. Hepatology, 2022, 76(4): 1203-1218. DOI: 10.1002/hep.32613.

Please choose a citation manager

Content to export